PT  - JOURNAL ARTICLE
AU  - Yu Kang
AU  - Tiffany Chen
AU  - David Mui
AU  - Victor Ferrari
AU  - Dinesh Jagasia
AU  - Marielle Scherrer-Crosbie
AU  - Yucheng Chen
AU  - Yuchi Han
TI  - Cardiovascular manifestations and treatment considerations in COVID-19
AID  - 10.1136/heartjnl-2020-317056
DP  - 2020 Aug 01
TA  - Heart
PG  - 1132--1141
VI  - 106
IP  - 15
4099  - http://heart.bmj.com/content/106/15/1132.short
4100  - http://heart.bmj.com/content/106/15/1132.full
SO  - Heart2020 Aug 01; 106
AB  - Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, COVID-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of COVID-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support.